CGTN: China Unveils New Discoveries From Sanxingdui, Over 500 Items Unearthed
Chinese archaeologists announced on Saturday that some new major discoveries have been made at the legendary Sanxingdui Ruins site in southwest China, helping shed light on the cultural origins of the Chinese nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210320005008/en/
Archaeologists have found six new sacrificial pits and unearthed more than 500 items dating back about 3,000 years at the Sanxingdui Ruins in Sichuan Province, the National Cultural Heritage Administration (NCHA) announced in the provincial capital Chengdu.
Over 500 precious cultural relics discovered
Ranging from 3.5 to 19 square meters, these six sacrificial pits, which were discovered from November 2019 to May 2020, are in rectangular shape, according to NCHA. Among them, pits No.3, No.4, No.5 and No.6 have been excavated to the utensil layer so far, while pits No.7 and No.8 are being backfilled.
Together they form an area in which people of the ancient Shu civilization offered sacrifices to heaven, Earth and their ancestors, and prayed for prosperity and peace, according to Tang Fei, head of the excavation team at Sanxingdui and chief of the Sichuan Provincial Cultural Relics and Archaeology Research Institute.
The discoveries have shown the distinctiveness of the Shu civilization and the diversity of the Chinese civilization, said Ran Honglin, another researcher with the institute.
In addition, over 500 pieces of important cultural relics have been unearthed from these six pits, including the fragments of gold masks, bird-shaped gold ornaments, gold foil, painted bronze head portraits, giant bronze masks, bronze sacred tree, ivory, fragments of exquisite tooth carvings, jade cong and jade tools.
A gold mask has been unearthed at the No.5 sacrificial pit. With an area of about three square meters, it is the smallest pit, but it's where the most gold pieces were unearthed, according to archaeologists.
During the process, archaeologists have made full use of modern scientific and technological means to build an archaeological excavation cabin, integrated excavation platform and multi-functional excavation operation system.
With the support of professional teams of multiple disciplines and institutions, they have formed an integrated work mode combining traditional archaeology, laboratory archaeology, technological archaeology as well as the protection of cultural relics. The combination will ensure the high quality and high level of archaeological work, NCHA said at the conference.
Meanwhile, the NCHA has identified the "Research on the Civilization Process of Bashu in Sichuan-Chongqing Region" as a major program of the "Archaeological China" project, aiming to conduct in-depth study on the evolution of civilization in the region and its integration into the overall cultural landscape of the pluralistic unity of the Chinese nation.
Located in the city of Guanghan, some 40 kilometers from Sichuan's provincial capital Chengdu, the Sanxingdui Ruins site is regarded one of the most important archaeological discoveries in the 20th century. The excavation has lasted for nearly 100 years since the first discovery in the late 1920s.
In 1986, archaeologists found two large-scale sacrificial pits dating back to the Shang Dynasty (1600-1046 BC). Thousands of rare treasures were discovered from the two pits.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210320005008/en/
Contact information
Media:
Jiang Simin
jiang.simin@cgtn.com
+86 18826553286
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
